CAPITOL HEALTH LIMITED (CAJ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CAJ - CAPITOL HEALTH LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.36
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.305

22 Jul
2024

-0.005

OPEN

$0.31

-1.61%

HIGH

$0.31

1,020,176

LOW

$0.31

TARGET
$0.322 5.6% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
CAJ: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 1.1 35.0 xxx
DPS (cps) xxx 1.0 1.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx 0.0% 0.0% xxx
PE Ratio xxx N/A 0.9 xxx
Dividend Yield xxx N/A 3.2% xxx
Div Pay Ratio(%) xxx N/A 2.9% xxx

Dividend yield today if purchased 3 years ago: 2.70%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.23

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/03 - ex-div 0.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-1.1
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx209.6 M
Book Value Per Share xxxxxxxxxxxxxxx12.9
Net Operating Cash Flow xxxxxxxxxxxxxxx37.5 M
Net Profit Margin xxxxxxxxxxxxxxx-5.44 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-7.85 %
Return on Invested Capital xxxxxxxxxxxxxxx-4.70 %
Return on Assets xxxxxxxxxxxxxxx-3.87 %
Return on Equity xxxxxxxxxxxxxxx-7.85 %
Return on Total Capital xxxxxxxxxxxxxxx6.08 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx10.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx12 M
Long Term Debt xxxxxxxxxxxxxxx123 M
Total Debt xxxxxxxxxxxxxxx135 M
Goodwill - Gross xxxxxxxxxxxxxxx157 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx19 M
Price To Book Value xxxxxxxxxxxxxxx2.09

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx16.8 M
Capex % of Sales xxxxxxxxxxxxxxx8.04 %
Cost of Goods Sold xxxxxxxxxxxxxxx172 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx22 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

25/06/2024

3

Downgrade to Hold from Buy

$0.326

6.89%

Bell Potter assesses Capitol Health post the merger proposal with Integral Diagnostics ((IDX)), which offers a premium and is likely to succeed with board support.

The broker points to a decline of –2.6% year-over-year in GP attendance performance, driven primarily by Telehealth and Phone GP services, although face-to-face visits are on the rise.

Diagnostic imaging services and benefits have shown solid growth, with benefits maintaining double digits for the second consecutive month.

Bell Potter notes the merger is expected to close by late 2024.

The rating is downgraded to Hold from Buy and the target price rises to $0.326 from $0.29.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 1.00 cents and EPS of 69.00 cents.
Bell Potter forecasts a full year FY25 dividend of 1.00 cents and EPS of 93.00 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

19/06/2024

3

Market Weight

$0.27

-11.48%

While noting the attractiveness in creating a large, listed player in radiology via the merger of Integral Diagnostics and Capitol Health, Wilsons notes achieving management's -$10m target for cost synergies will be vital to ultimate success.

Capitol has long been regarded as an attractive target, according to the broker, and its clinics will markedly expand Integral’s presence in Victoria, Western Australia and Tasmainia.

Scale is the most significant benefit of a merger, suggest the analysts, with the combined entity matching the size of Lumus Imaging, with I-MED still a significantly larger peer.

Integral intends to acquire 100% of Capitol's shares for $0.326/share, a 33% increase on the last close for Capitol shares. The broker's Market Weight rating and 27c target are kept, but both are under review.

FORECAST
Wilsons forecasts a full year FY24 dividend of 1.00 cents and EPS of 1.00 cents.
Wilsons forecasts a full year FY25 dividend of 1.10 cents and EPS of 1.30 cents.

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

CAJ STOCK CHART

FNArena News on CAJ

1
In Brief: Airlines, Pathology & Seek

Jul 12 2024 - Weekly Reports
2
Weekly Ratings, Targets, Forecast Changes – 28-06-24

Jul 01 2024 - Weekly Reports
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Australian Broker Call *Extra* Edition – Jun 19, 2024

Jun 19 2024 - Daily Market Reports
5
ESG Focus: The Little Big Things – 15-05-2024

May 15 2024 - ESG Focus

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia